We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single-Cell RNA Sequencing Identifies Mechanisms Underlying Autoimmune Diseases

By LabMedica International staff writers
Posted on 11 Apr 2022

Two recently published studies were designed to help understand how gene expression patterns are cell-type and context specific and can explain observed variation in immune cell function among individuals. More...

These studies also identified causal links between genome-wide analyses and expression quantitative trait loci, identifying potential mechanisms underlying autoimmune diseases.

To identify how implicated loci affect gene expression in immune cells from individuals from different populations, two research groups performed single-cell RNA sequencing of immune cells, with each study investigating hundreds of individuals and more than one million immune cells.

The studies examined both proximal (cis) and distal (trans) genetic variants affecting gene expression in 14 different immune cell types. One research group studied healthy individuals of both European and Asian descent, as well as individuals diagnosed with systemic lupus erythematosus. The other group performed a population-based study investigating how segregating alleles contribute to variation in immune function.

The studies capitalized on the Garvan Institute of Medical Research (Darlinghurst, Australia) OneK1K cohort, which consists of single-cell RNA sequencing (scRNA-seq) data from 1.27 million peripheral blood mononuclear cells (PMBCs) collected from 982 donors.

The investigators worked in the context of The Garvan-Weizmann Centre for Cellular Genomics Molecular Services, which provided state-of-the-art advanced single cell platforms. The Centre combines the expertise of the The Garvan Institute of Medical Research with that of the Weizmann Institute of Science (Rehovot, Israel). The research facility offered services in single cell Immuno-profiling, ATAC sequencing, and Multiomics (ATAC+RNA Sequencing), and its Flow Services component provided cytometry services as well as expert consultation in the field of cytometry.

Over the course of the work, the investigators developed a framework for the classification of individual cells, and by combining the scRNA-seq data with genotype data, they mapped the genetic effects on gene expression in each of 14 immune cell types and identified 26,597 independent cis–expression quantitative trait loci (eQTLs). They showed that most of these had an allelic effect on gene expression that was cell type–specific. These results replicated in two independent cohorts, one of which comprised individuals with a different ancestry to the discovery cohort. Over all loci, the discovery and replication cohorts had a concordance of allelic direction ranging from 72.2 to 98.1% across cell types. In addition, the investigators integrated genetic association data for seven common autoimmune diseases and identified significant enrichment of genetic effects operating in a cell type–specific manner.

“We analyzed the genomic profile of over one million cells from 1,000 people to identify a fingerprint linking genetic markers to diseases such as multiple sclerosis, rheumatoid arthritis, lupus, type I diabetes, spondylitis, inflammatory bowel disease, and Crohn’s disease,” said senior author Dr. Joseph Powell, director of the Garvan Institute of Medical Research. “We were able to do this using single cell sequencing, a new technology that allows us to detect subtle changes in individual cells. Some autoimmune diseases can be notoriously difficult to treat. Because of our immune system’s complexity, and how vastly it varies between individuals, we do not currently have a good understanding of why a treatment works well in some people but not in others. The greatest insight from this work will be identification of therapeutic targets and defining sub-populations of immune disease, which can then refine clinical trials to assess drug effectiveness.”

The studies were published in the April 8, 2022, online edition of the journal Science.

Related Links:
Garvan Institute of Medical Research 
Weizmann Institute of Science 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.